ahlam1399
07-22-2016, 09:47 AM
BRIEF-Amgen and UCB submit biologics license application for romosozumab to the FDA
* Amgen and UCB submit biologics license application forromosozumab to the FDAhttp://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=u23GnM0BIRk:--72NpDG9XI:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=u23GnM0BIRk:--72NpDG9XI:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=u23GnM0BIRk:--72NpDG9XI:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=u23GnM0BIRk:--72NpDG9XI:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=u23GnM0BIRk:--72NpDG9XI:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/u23GnM0BIRk
* Amgen and UCB submit biologics license application forromosozumab to the FDAhttp://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=u23GnM0BIRk:--72NpDG9XI:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=u23GnM0BIRk:--72NpDG9XI:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=u23GnM0BIRk:--72NpDG9XI:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=u23GnM0BIRk:--72NpDG9XI:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=u23GnM0BIRk:--72NpDG9XI:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/u23GnM0BIRk